New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - sofosbuvir 400mg;  ;  ;  ; velpatasvir 100mg;  ;  ;   - tablet - 400mg/100mg - active: sofosbuvir 400mg       velpatasvir 100mg       excipient: copovidone croscarmellose sodium opadry ii pink 85f94644 magnesium stearate microcrystalline cellulose - indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults.

Israel - English - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - film coated tablets - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adults.

Israel - English - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - film coated tablets - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adults.

Israel - English - Ministry of Health

gilead sciences israel ltd - ledipasvir; sofosbuvir - film coated tablets - ledipasvir 90 mg; sofosbuvir 400 mg - sofosbuvir and ledipasvir - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - sofosbuvir 400mg;  ;  ;   - film coated tablet - 400 mg - active: sofosbuvir 400mg       excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose opadry yellow 85f92259 purified water - sovaldi is indicated in combination with other agents for the treatment of chronic hepatitis c (chc) in adults and in pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 2 or 3, without cirrhosis or with compensated cirrhosis.

European Union - English - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir - hepatitis c, chronic - antivirals for systemic use - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).for hepatitis c virus (hcv) genotype specific activity, see sections 4.4 and 5.1.sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).for hepatitis c virus (hcv) genotype specific activity, see sections 4.4 and 5.1.

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited mylan laboratories limited, plot no.564/a/22, - ledipasvir/ sofosbuvir - tablet - each tablet contains: ledipasvir/ sofosbuvir 90… - sofosbuvir and ledipasvir

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited mylan laboratories limited, plot no.564/a/22, - sofosbuvir and velpatasvir - tablet - each tablet contains: sofosbuvir and velpatasvir… - direct acting antivirals

Israel - English - Ministry of Health

gilead sciences israel ltd - tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - viread is indicated for the treatment of :1. hiv 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of hiv. 2. chronic hepatitis b in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease

Israel - English - Ministry of Health

gilead sciences israel ltd - tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - viread is indicated for the treatment of :1. hiv 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of hiv. 2. chronic hepatitis b in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease